Google DeepMind has expanded its AlphaFold AI system to not only predict the structure of proteins, but also to model how proteins interact with other cell structures, including DNA, RNA, and small ...
Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. Nimbus Therapeutics and Eli Lilly announce their ...
Seattle biotech startup Rhizome Research has emerged from stealth with technology for creating small-molecule drug candidates ...
TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...
Isomorphic Labs, the London-based, drug discovery–focused spinout of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical giants, Eli ...
Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...
Drug discovery has long relied on two key strategies: target-based and phenotypic screening. Recombinant technologies and genomics opened the door to modern target-based drug discovery (TBDD), ...
This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback